

**AMENDMENTS TO THE CLAIMS**

Claims 1-34 (Canceled)

35. (Currently amended) A transgenic mouse comprising a disruption in an endogenous intestinal alkaline phosphatase gene, wherein where the disruption is homozygous, the transgenic mouse lacks production of functional intestinal alkaline phosphatase protein and exhibits, relative to a wild-type mouse, ~~a nociceptive abnormality or~~ abnormal activity level.

36. (Canceled)

37. (Canceled)

38. (Previously added) The transgenic mouse of claim 35, wherein the abnormal activity level comprises decreased activity.

39. (Previously added) The transgenic mouse of claim 38, wherein the decreased activity is characterized by a decreased velocity during ambulatory episodes in an open field test.

40. (Currently amended) A method of producing a transgenic mouse comprising a disruption in an endogenous intestinal alkaline phosphatase gene, the method comprising:

- (a) introducing an intestinal alkaline phosphatase gene targeting vector into a murine embryonic stem cell;
- (b) introducing the cell into a blastocyst;
- (c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and
- (d) breeding the chimeric mouse to produce the transgenic mouse, wherein where the disruption is homozygous, the mouse lacks production of functional intestinal alkaline phosphatase protein and exhibits ~~a nociceptive abnormality or an~~ activity level abnormality, relative to a wild-type mouse.

41. (Previously added) A cell obtained from the transgenic mouse of claim 35.

Claims 42-46 (Canceled)